The Exchange has sought clarification from Beta Drugs Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
BETA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The NSE has asked Beta Drugs Limited to clarify a compliance issue for the quarter ended 31-Mar-2025. Specifically, the financial results filed by the company do not match the format prescribed by SEBI under Regulation 33 of the Listing Obligations and Disclosure Requirements Regulations, 2015. The company is yet to submit its response to the exchange. This appears to be a routine compliance query regarding the presentation format of quarterly results rather than a substantive concern about the numbers themselves. The stock may see minor attention until the company responds with a corrected filing.
This is a procedural compliance flag rather than a penalty or investigation, so the impact on shareholders is likely minimal. Investors should watch for the company's response and any revised financial filing to ensure the underlying results are unaffected.